The third generation of nutrient-stimulated hormone-based (NuSH) anti-obesity medications (AOM), which includes co- and tri-agonists that combine peptides such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), amylin, and glucagon, is poised to commence clinical trials in adolescents. The gene discussed is GLP1R; the disease is Obesity.